Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


SudaScan combats meth

This article was originally published in The Tan Sheet

Executive Summary

Bartell Drugs launches a retail pilot program aiming to curtail purchases of pseudoephedrine products exceeding the 3.6 g monthly limit mandated by the federal Combat Meth Act. The program, launched in the Washington state-based drug store chain's Lynnwood, Wash., location, employs SudaScan, a patent-pending software and database program produced by technology firm Pharmitas that eliminates the need for paper-based logs. The handheld device "instantaneously reads and decodes two-dimensional driver's license barcodes and UPC product labels to enter the required information, reducing the logging time from more than three minutes to about 13 seconds," Bellevue, Wash.-based Pharmitas states. Following the 90-day pilot program, Bartell will make a decision on whether to implement the SudaScan system in its other stores. Pharmitas say it currently is in discussions with a number of pharmacy and retail chains about adopting SudaScan nationwide...

You may also be interested in...

Pharmitas’ Pseudoephedrine Scanner Pilot Could Lead To More Retailer Deals

Pharmitas' pilot program of the software and database system it developed to electronically scan and track sales of pseudoephedrine-containing drugs is nearing completion and is generating interest from retailers looking for an easier method of complying with log-book requirements mandated by the federal Combat Meth Act, the firm says

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts